The war of words over the proposed Pfizer-AstraZeneca merger was already hot. Now, it's almost boiling. And as usual when the heat is on, some people can't handle it. They boil over. Here's what people are hearing.
It turns out that Boehringer Ingelheim's popular anticoagulant Pradaxa is safer than many people think. That is the finding of the FDA after taking another look at the side effects of the drug compared to the old standard warfarin and this time looking at a much larger and older patient base.
Two key investigational drugs came through in mid-stage studies, providing some ballast for the drugmaker as it boasts the value of its pipeline in an effort to ward off an unwelcome bid by Pfizer--or at least drive up the asking price.
Another day, another onslaught of Pfizer-AstraZeneca news. We admit to a slight case of Pfizer Pfatigue, and if yesterday's web traffic is any guide, readers are similarly afflicted. But the $100 billion-plus merger proposal is massive, with enormous potential side effects, so even the rhetoric is worth consideration. Here are the highlights, from hints of a new bid to Pfizer CEO Ian Read's purported reassurances to U.S. lawmakers' heightened job worries.
The leaders of Pfizer and AstraZeneca are taking turns making their cases to British lawmakers, with the former trying to mollify locals afraid that its planned $106 billion buyout would maim U.K. R&D and the latter working to mount a defense in its home country.
With various U.K. media groups adding their voices to a crescendo of criticism over Pfizer's proposed $106 billion-plus buyout of AstraZeneca, the company's R&D chief is continuing to try and insist that this deal makes really good sense from a drug research perspective. But he's finding few buyers for that argument after years of Big Pharma reorganizations and mass layoffs in R&D.
With U.K. lawmakers skeptical of Pfizer's commitment to keep AstraZeneca jobs and AstraZeneca science in the U.K., Pfizer over the weekend released a series of videos focusing on that science--and downplaying the tax benefits CEO Ian Read crowed about so loudly when first confirming his company's trans-Atlantic bid.
Given the eyebrow-raising cash component in Celgene's new deal with Nogra, we thought it would be fun to list the top 10 upfronts paid for experimental drugs, ranked simply according to the cash included in the upfront--no surer sign of what a company really thinks about the potential of an experimental therapy or portfolio.
Last March, Pfizer announced it would file for approval for its meningitis B candidate. Now, it has positive results from a pair of midstage trials for the jab that will keep it on track for expedited approval--and a showdown with Novartis' Bexsero.
Pfizer has managed to upset just about everybody with its $106 billion takeover offer for U.K.-based AstraZeneca. AstraZeneca doesn't like it. The U.K. Parliament is concerned about possible losses of job and status. Some U.S. politicians see it as a tax dodge, and even a couple of governors fear Pfizer will slash AstraZeneca jobs in their states.